PharmAla Biotech forms joint venture for APA-01 drug development
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
May 13, 2026 8:30 AM EDTTORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) (PharmAla or the Company), a leader in the research, development, and manufacturing of clinical-grade MDMA and novel MDXX-class compounds, today announced that it has executed a definitive SPV Formation, Shareholder and License Agreement (the Definitive Agreement) with Aluvaris Inc. (Aluvaris) and Diteba Inc. (Diteba). The Definitive Agreement establishes a jointly-owned special purpose vehicle called Restora Neurosciences (the Restora or the... More
